Literature DB >> 26668625

Peritoneal dialysis treatment for severe lupus nephritis patients complicated with essential organ dysfunction.

Yan Zhou1, Yusheng Yu1, Zheng Tang1, Shijun Li1, Weixin Hu1, Chunlei Luo1, Zhihong Liu1.   

Abstract

The aim of the present study was to evaluate the clinical efficacy of peritoneal dialysis (PD) in patients with severe lupus nephritis (LN) complicated with organ dysfunction. In total, 13 severe LN patients complicated with multiple-organ dysfunction, who underwent PD treatment between November 2003 and September 2010, were enrolled in the study. Six patients received methylprednisolone pulse therapy due to lupus activity and progressive renal failure. These patients were complicated with severe edema, cardiac insufficiency and severe hypoalbuminemia. PD was applied to the patients, followed by the administration of immunosuppressants. Patients were followed-up to review the parameters of renal function, the immunological indexes and the systemic lupus erythematosus disease activity index. The results indicated that the general state of health was markedly improved following PD treatment, with edema abatement and improvement of heart function and physical strength. Serum creatinine levels significantly decreased from 6.3±1.6 to 2.6±1.0 mg/dl. A total of 10 cases ceased PD treatment during the follow-up, while three cases continued PD to the end of the follow-up period. The levels of albumin and hemoglobin exhibited a marked increase from 29.7±5.7 to 35.2±5.5 g/l and 8.7±1.8 to 9.8±1.8 g/l, respectively. There was one case of peritonitis, one case of peritoneal leakage and two cases of pneumonia. Therefore, PD may be a successful treatment method for severe LN patients complicated with essential organ dysfunction. PD not only improved the symptoms of edema and heart failure, but also played an important role in preserving residual renal function and improving the nutritional state of the patients. Thus, PD can be considered as a treatment option for patients with severe LN associated with acute kidney injury, however, selecting a suitable immunosuppressant during PD treatment is essential.

Entities:  

Keywords:  immunosuppressant; peritoneal dialysis; residual renal function; systemic lupus erythematosus

Year:  2015        PMID: 26668625      PMCID: PMC4665972          DOI: 10.3892/etm.2015.2799

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  26 in total

Review 1.  Malnutrition, inflammation, and atherosclerosis in peritoneal dialysis patients.

Authors:  P Stenvinkel; S H Chung; O Heimbürger; B Lindholm
Journal:  Perit Dial Int       Date:  2001       Impact factor: 1.756

Review 2.  Renal replacement therapy in lupus nephritis.

Authors:  Anke Rietveld; Jo H M Berden
Journal:  Nephrol Dial Transplant       Date:  2008-07-28       Impact factor: 5.992

3.  Impaired outcome of continuous ambulatory peritoneal dialysis in immunosuppressed patients.

Authors:  P A Andrews; K J Warr; J A Hicks; J S Cameron
Journal:  Nephrol Dial Transplant       Date:  1996-06       Impact factor: 5.992

4.  Infective endocarditis associated with acute renal failure: Repeat renal biopsy and successful recovery.

Authors:  Aifeng Wang; Yongping Wang; Guobao Wang; Zhanmei Zhou; Xiaobing Yang
Journal:  Exp Ther Med       Date:  2010-05-01       Impact factor: 2.447

5.  Long-term efficacy of intermittent peritoneal dialysis using various doses.

Authors:  Zhi-Yong Zhang; Chun-Hua Zhou; Ming-Xu Li; Yong-Wu Yu
Journal:  Exp Ther Med       Date:  2011-12-30       Impact factor: 2.447

6.  Early introduction of peritoneal dialysis may improve survival in severe sepsis.

Authors:  Katalin Szakszon; István Csízy; Tamás Szabó
Journal:  Pediatr Emerg Care       Date:  2009-09       Impact factor: 1.454

Review 7.  End-stage renal disease in systemic lupus erythematosus.

Authors:  J S Cheigh; K H Stenzel
Journal:  Am J Kidney Dis       Date:  1993-01       Impact factor: 8.860

8.  Pauci-immune necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus.

Authors:  A Fayaz; Y Pirson; J-P Cosyns; J Yango; M Lambert
Journal:  Clin Nephrol       Date:  2008-04       Impact factor: 0.975

9.  Specificity of anti-SSB as a diagnostic marker for the classification of systemic lupus erythematosus.

Authors:  Li Rao; Guiyan Liu; Chunfen Li; Yajuan Li; Zhiguo Wang; Zijiao Zhou; Shengquan Tong; Xianming Wu
Journal:  Exp Ther Med       Date:  2013-04-08       Impact factor: 2.447

10.  Clinical application of right low-position modified peritoneal dialysis catheterization.

Authors:  Wei Ren; Wei Chen; Hui-Xuan Pan; Lei Lan; Peng Wang; Ye-Hua Huang; Ming Kong; Yan Wang
Journal:  Exp Ther Med       Date:  2012-11-12       Impact factor: 2.447

View more
  1 in total

Review 1.  Two cases demonstrating thalidomide's efficacy in refractory lupus nephritis.

Authors:  Rita Raturi; Avani A Patel; John D Carter
Journal:  Clin Rheumatol       Date:  2016-12-20       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.